Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45


A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma.

Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM.

Cancers (Basel). 2018 May 25;10(6). pii: E160. doi: 10.3390/cancers10060160.


Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.

Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC, Nawrocki ST.

Oncotarget. 2017 Sep 30;8(49):86769-86783. doi: 10.18632/oncotarget.21423. eCollection 2017 Oct 17.


Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.

Mita MM, Mita AC, Moseley JL, Poon J, Small KA, Jou YM, Kirschmeier P, Zhang D, Zhu Y, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig SJ, Bannerji R, Shapiro GI.

Br J Cancer. 2017 Oct 24;117(9):1258-1268. doi: 10.1038/bjc.2017.288. Epub 2017 Aug 31.


Statins and pancreatic cancer.

Gong J, Sachdev E, Robbins LA, Lin E, Hendifar AE, Mita MM.

Oncol Lett. 2017 Mar;13(3):1035-1040. doi: 10.3892/ol.2017.5572. Epub 2017 Jan 4.


Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Mita MM, Nemunaitis J, Grilley-Olson J, El-Rayes B, Bekaii-Saab T, Harvey RD, Marshall J, Zhang X, Strout V.

Target Oncol. 2016 Dec;11(6):807-814.


Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

Gong J, Sachdev E, Mita AC, Mita MM.

World J Methodol. 2016 Mar 26;6(1):25-42. doi: 10.5662/wjm.v6.i1.25. eCollection 2016 Mar 26. Review.


Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.

Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA 3rd, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC.

Clin Cancer Res. 2016 Jul 1;22(13):3157-63. doi: 10.1158/1078-0432.CCR-15-2548. Epub 2016 Feb 4.


Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.

Sarantopoulos J, Mita MM, Birrer MJ, Cranmer LD, Campos LT, Zhang X, Bristow P, Kaito H, Strout V, Camacho LH.

Target Oncol. 2016 Jun;11(3):317-27. doi: 10.1007/s11523-015-0394-5.


Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.

Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS.

Int J Clin Pharmacol Ther. 2015 Jul;53(7):563-72. doi: 10.5414/CP202359.


Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.

Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC, Nawrocki ST.

Mol Cancer Ther. 2015 Jun;14(6):1404-13. doi: 10.1158/1535-7163.MCT-14-1036. Epub 2015 Mar 25.


Pharmacokinetic study of aldoxorubicin in patients with solid tumors.

Mita MM, Natale RB, Wolin EM, Laabs B, Dinh H, Wieland S, Levitt DJ, Mita AC.

Invest New Drugs. 2015 Apr;33(2):341-8. doi: 10.1007/s10637-014-0183-5. Epub 2014 Nov 12.


Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.

Sarantopoulos J, Mita AC, Wade JL, Morris JC, Rixe O, Mita MM, Dedieu JF, Wack C, Kassalow L, Lockhart AC.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1113-24. doi: 10.1007/s00280-014-2572-z. Epub 2014 Oct 12.


Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.

Lockhart AC, Sundaram S, Sarantopoulos J, Mita MM, Wang-Gillam A, Moseley JL, Barber SL, Lane AR, Wack C, Kassalow L, Dedieu JF, Mita AC.

Invest New Drugs. 2014 Dec;32(6):1236-45. doi: 10.1007/s10637-014-0145-y. Epub 2014 Aug 13.


Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells.

Gong J, Mita MM.

Front Oncol. 2014 Jun 26;4:167. doi: 10.3389/fonc.2014.00167. eCollection 2014. Review.


Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, Statkevich P, Zhu Y, Yao SL, Small K, Bannerji R, Shapiro CL.

Clin Breast Cancer. 2014 Jun;14(3):169-76. doi: 10.1016/j.clbc.2013.10.016. Epub 2013 Oct 26.


Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.

Mita MM, Gong J, Chawla SP.

Expert Rev Clin Pharmacol. 2013 Sep;6(5):465-82. doi: 10.1586/17512433.2013.827397. Epub 2013 Aug 23. Review. Erratum in: Expert Rev Clin Pharmacol. 2013 Nov;6(6):732.


A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.

Nemunaitis J, Hochster HS, Lustgarten S, Rhodes R, Ebbinghaus S, Turner CD, Dodion PF, Mita MM.

Clin Oncol (R Coll Radiol). 2013 Jun;25(6):336-42. doi: 10.1016/j.clon.2013.02.005. Epub 2013 Apr 21.


Vascular-disrupting agents in oncology.

Mita MM, Sargsyan L, Mita AC, Spear M.

Expert Opin Investig Drugs. 2013 Mar;22(3):317-28. doi: 10.1517/13543784.2013.759557. Epub 2013 Jan 15. Review.


Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.

Mita MM, Poplin E, Britten CD, Tap WD, Rubin EH, Scott BB, Berk L, Rivera VM, Loewy JW, Dodion P, Haluska F, Sarantopoulos J, Mita A, Tolcher A.

Ann Oncol. 2013 Apr;24(4):1104-11. doi: 10.1093/annonc/mds602. Epub 2012 Dec 4.


Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?

Mita AC, Figlin R, Mita MM.

Clin Cancer Res. 2012 Dec 15;18(24):6574-9. doi: 10.1158/1078-0432.CCR-12-1584. Epub 2012 Oct 22.


Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.

Nemunaitis J, Mita A, Stephenson J, Mita MM, Sarantopoulos J, Padmanabhan-Iyer S, Nanda N, Gleich L, Benichou AC, Craig A.

Cancer Chemother Pharmacol. 2013 Jan;71(1):35-41. doi: 10.1007/s00280-012-1963-2. Epub 2012 Oct 4.


Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J.

Clin Cancer Res. 2012 Jun 15;18(12):3414-27. doi: 10.1158/1078-0432.CCR-11-3369. Epub 2012 Apr 17.


Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.

Berk L, Mita MM, Kreisberg J, Bedrosian CL, Tolcher AW, Clackson T, Rivera VM.

Cancer Chemother Pharmacol. 2012 May;69(5):1369-77. doi: 10.1007/s00280-011-1813-7. Epub 2012 Jan 10.


Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD.

J Clin Oncol. 2012 Jan 1;30(1):78-84. doi: 10.1200/JCO.2011.35.6329. Epub 2011 Nov 7.


Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.

Mita AC, Papadopoulos K, de Jonge MJ, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QS, Tolcher AW, Wood L, McCarthy S, Hamilton M, Iwata K, Wacker B, Witt K, Rowinsky EK.

Br J Cancer. 2011 Sep 27;105(7):938-44. doi: 10.1038/bjc.2011.332. Epub 2011 Aug 30.


Heat shock proteins: a potential anticancer target.

Sankhala KK, Mita MM, Mita AC, Takimoto CH.

Curr Drug Targets. 2011 Dec;12(14):2001-8. Review.


Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.

Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC.

Target Oncol. 2011 Jun;6(2):69-94. doi: 10.1007/s11523-011-0178-5. Epub 2011 May 4. Review.


Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.

Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP, Federico KC, Reich SD, Romero O, Malburg L, Pilat M, Lloyd GK, Neuteboom ST, Cropp G, Ashton E, LoRusso PM.

Clin Cancer Res. 2010 Dec 1;16(23):5892-9. doi: 10.1158/1078-0432.CCR-10-1096.


Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ, Nawrocki ST.

Clin Cancer Res. 2010 Jan 1;16(1):141-53. doi: 10.1158/1078-0432.CCR-09-1385. Epub 2009 Dec 22.


Targeting sarcomas: novel biological agents and future perspectives.

Mahalingam D, Mita A, Sankhala K, Swords R, Kelly K, Giles F, Mita MM.

Curr Drug Targets. 2009 Oct;10(10):937-49. Review.


Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.

Carew JS, Medina EC, Esquivel JA 2nd, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, Giles FJ, Nawrocki ST.

J Cell Mol Med. 2010 Oct;14(10):2448-59. doi: 10.1111/j.1582-4934.2009.00832.x.


Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK.

J Clin Oncol. 2009 Jul 1;27(19):3133-40. doi: 10.1200/JCO.2008.20.4495. Epub 2009 May 18.


Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development.

Mahalingam D, Mita A, Mita MM, Nawrocki ST, Giles FJ.

Curr Probl Cancer. 2009 Mar-Apr;33(2):73-111. doi: 10.1016/j.currproblcancer.2009.03.001. Review. No abstract available.


Targeting the mTOR pathway using deforolimus in cancer therapy.

Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM.

Future Oncol. 2009 Apr;5(3):291-303. doi: 10.2217/fon.09.9. Review.


Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, Preston GG, Mita MM, Rodon J, Mays T, Yeh IT, O'Rourke P, Takimoto CH, Dancey JE, Chen H, Tolcher AW.

Cancer Chemother Pharmacol. 2009 May;63(6):1065-71. doi: 10.1007/s00280-008-0811-x. Epub 2008 Sep 16.


Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.

Mita AC, Mita MM, Nawrocki ST, Giles FJ.

Clin Cancer Res. 2008 Aug 15;14(16):5000-5. doi: 10.1158/1078-0432.CCR-08-0746. Review.


Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW.

J Clin Oncol. 2008 Jan 20;26(3):361-7. doi: 10.1200/JCO.2007.12.0345.


The role of mTOR inhibitors for treatment of sarcomas.

Mita MM, Tolcher AW.

Curr Oncol Rep. 2007 Jul;9(4):316-22. Review.


Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.

Mita AC, Olszanski AJ, Walovitch RC, Perez RP, MacKay K, Tuck DP, Simmons C, Hammond S, Mita MM, Beeram M, Stone AJ, Rowinsky EK, Lewis LD.

Clin Cancer Res. 2007 Jun 1;13(11):3293-301.


Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.

Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, Schwartz G, Beeram M, Hidalgo M, Mita MM, Wolf J, Nadler P, Rowinsky EK.

Clin Cancer Res. 2006 Dec 15;12(24):7406-13.


A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.

Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A.

Cancer Chemother Pharmacol. 2007 Feb;59(2):165-74. Epub 2006 May 31.


A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, Tolcher AW.

Ann Oncol. 2006 Feb;17(2):313-21. Epub 2005 Dec 1.


Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.

Mita AC, Mita MM, Rowinsky EK.

Clin Colorectal Cancer. 2004 Jul;4(2):107-23. Review.


The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.

Mita MM, Mita A, Rowinsky EK.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S169-77. Review.


Mammalian target of rapamycin: a new molecular target for breast cancer.

Mita MM, Mita A, Rowinsky EK.

Clin Breast Cancer. 2003 Jun;4(2):126-37. Review.


Supplemental Content

Support Center